Form 4: Artiva Biotherapeutics COO Jennifer Bush Reports Acquisition of 50,000 Shares
SEC Form 4 Filing
Jennifer Bush, COO, CLO, Secretary, and Compliance Officer of Artiva Biotherapeutics, reports acquiring 50,000 shares of common stock and disposing of 72,799 shares.
Summary
- On September 12, 2024, Jennifer Bush, the COO, CLO, Secretary, and Compliance Officer of Artiva Biotherapeutics, acquired 50,000 shares of common stock.
- The acquisition was part of a restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
- The price of the acquired shares was $0.
- Bush also disposed of 72,799 shares.
- Following the reported transactions, Bush beneficially owns 72,799 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The grant of restricted stock units aligns the executive's interests with those of the shareholders.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of shares by a key executive could be viewed positively by shareholders, indicating confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of transaction: Acquisition of 50,000 shares of common stock and disposal of 72,799 shares. |
| 09/13/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.